Meet our partners
Global Partner
Bristol-Myers Squibb
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Read more at

Mar 2016 Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.

Feb 2016 Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care More Accessible in High-Risk U.S. Communities

Feb 2016 Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan

From the OneStart San Francisco Bootcamp 2016 

Panel Discussion

Panel Discussion: Accessing and Interacting with Industry
  • Thomas Luby, PhD, Senior Director of New Ventures, Johnson & Johnson innovation, Boston (Chair)
  • Sharon Cload, VP Molecular Discovery Technologies, Bristol-Myers Squibb
  • Lucy Perez, PhD, Partner, McKinsey and Company
  • Sam Wu, Managing Director, MedImmune Ventures
  • David Wilson, PhD, VP Biologics, Teva Pharmaceuticals

Panel Discussion: Navigating Critical Decision Points

  • Percy Carter, PhD and MBA, Head of Discovery Chemistry, Bristol-Myers Squibb
  • Stephani Marrus, MA and MBA, Director, UCSF Entrepreneurship Center
  • Douglas Crawford, Associate Director/Managing Director, QB3/ Mission Bay Capital
  • Kathy Ku, Director of the Office of Technology Licensing and the Industrial Contracts Office, Stanford University
  • Catherine Tralau-Stewart, PhD, Assocaite Director, Catalyst Program- Therapeutics, UCSF
Art Bertelsen
Vice President, Bristol-Myers Squibb, Princeton, New Jersey + more
Vice President Research Collaborations at Bristol-Myers Squibb, Princeton, New Jersey
Timur Gungor
Principal Scientist and Alliance Manager at Bristol-Myers Squibb + more
Principal Scientist and Alliance Manager at Bristol-Myers Squibb
Marie Leithauser
Executive Director, Business Operations, Research at Bristol-Myers Squibb + more
Marie Leithauser holds the position of Executive Director of Business Operations for Bristol-Myers Squibb's Research organization. She has served on the New Jersey Commission on Cancer Research and as a member of the State Theater's Education Committee. Experience at Bristol-Myers Squibb: * Chief of Staff for Senior Vice President, Research * Focus Senior Team on high impact business issues and drive related strategy development * String of Pearls integration planning * Process simplification
Ruth Wexler
Executive Director at Bristol-Myers Squibb + more
Dr. Ruth Wexler joined the Bristol-Myers Squibb Company as Executive Director, Discovery Chemistry, (post-acquisition of DuPont Pharmaceuticals Company) and in the fall of 2002, she moved to Hopewell site in New Jersey where she currently heads the medicinal chemistry efforts directed at Cardiovascular Diseases. She was honored in 2004 as one of twelve Outstanding New Jersey Women in Research by the New Jersey Association for Biomedical Research. In 2011, she was a recipient of the Bristol-Myers Squibb Ondetti and Cushman award for her leadership role in the discovery of Eliquis®. She has been selected as the recipient of the 2015 E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances. Ruth has co-authored over 190 peer-reviewed scientific publications and patents, and has contributed several review articles and book chapters largely in the area of cardiovascular research.
Michael M. Miller
Associate Director at Bristol-Myers Squibb + more
Creative, results-oriented, passionate, and strategic R&D leader with expertise that spans the gamut from Process Development to Medicinal Chemistry and from Alliance Management to Business Development. Scientifically-driven business professional with strong interpersonal, communication, consulting, and project management skills. A proven leader of multi-disciplinary teams across functional areas who has contributed to the nomination of five (5) clinical candidates throughout his tenure within six (6) Therapeutic Areas within Discovery and the advancement of two (2) candidates within Process Development. Current Lead within Research Collaborations for Fibrosis, Immunoscience, Virology, and Discovery Platforms who not only manages established relationships, but also works closely with R&D senior management, corporate BD, Finance, and Legal to seek out new business opportunities and alliances. A leader of the organization’s strategic in-licensing and out-licensing activities.
Sharon Cload
VP, Molecular Discovery Technologies, Bristol-Myers Squibb + more
Dr. Sharon Cload, served as Vice President of Research at Adnexus Therapeutics, Inc. and served as Vice President of Discovery of Adnexus Therapeutics Inc. since July 2008. Dr. Cload has more than a decade of experience in lead discovery and managing biotech-pharma partnerships. Prior to joining Adnexus, she spent seven years in lead discovery and technology development at Archemix Corp., most recently as Vice President, Aptamer Discovery. From 1996 to 2000, Dr. Cload developed small molecule discovery technologies for both RNA and protein targets at Anadys Pharmaceuticals (formerly Scriptgen Pharmaceuticals), a biotechnology company. Dr. Cload holds a Ph.D. in Bio-Organic chemistry from Yale University, and was an NIH post-doctoral fellow with Peter Schultz at the University of California, Berkeley. Dr. Cload received her BA in Chemistry at New College of the University of South Florida.
Percy Carter
Head of Discovery Chemistry, Bristol-Myers Squibb + more
Head of Discovery Chemistry, Bristol-Myers Squibb
Teams Mentored